Furthermore, sCD163 levels are associated with prognosis, predict the risk of variceal bleeding (Rode et al., 2013; Waidmann et al., 2013) and correlates to disease severity and treatment response in patients with non-alcoholic fatty liver disease (Kazankov et al., 2015), alcoholic hepatitis (Sandahl et al., 2014), hepatitis B and C virus infection (Dultz et al., 2015; Laursen et al., 2018, 2019) and autoimmune liver diseases (Gronbaek et al., 2016a; Bossen et al., 2020, 2021). Here, CD163 is linked to autoimmune hepatitis.